Benova Mouth Rinse Study Shows Significant Reduction in Inflammatory Marker TNF-Alpha

Results from a University of Alabama study highlight the Benova Mouth Rinse System's ability to significantly reduce tumor necrosis factor-alpha (TNFα), a critical inflammatory marker, by 17% within just two minutes of application. This finding, presented at the 2025 Diabetic Limb Salvage Conference, underscores the rinse's potential to alleviate pain and support healing in conditions like oral mucositis and canker sores, which affect a significant portion of the population, including cancer patients undergoing chemotherapy.

The research, conducted by Dr. Daniel J. Gibson, focused on the rinse's mechanism of action in an in vitro model of inflamed oral mucosa, simulating tissue damage common in patients with chronic inflammatory wounds or those receiving cancer therapy. The study's results suggest a rapid anti-inflammatory effect without relying on traditional pain relievers or steroids, marking a promising advancement in oral care.

Bill Kling, co-founder of Benova, emphasized the correlation between the laboratory findings and anecdotal evidence from users who report quick relief from pain and inflammation. The Benova Mouth Rinse System, designed for conditions like stomatitis and oral mucositis, is already in use by healthcare professionals seeking to provide immediate relief to patients without the use of numbing agents or prescriptions.

The Diabetic Limb Salvage Conference, known for its focus on wound care and tissue regeneration, served as the platform for sharing these findings, highlighting the interdisciplinary interest in innovative treatments for inflammatory conditions. For more details on the study, the full scientific rationale and poster findings are available here.